Technology Innovation Institute Introduces World’s Most Powerful Open LLM: Falcon 180B
6.9.2023 16:20:00 EEST | Business Wire | Press release
The Technology Innovation Institute (TII) in the United Arab Emirates (UAE) is pushing the boundaries of generative AI once again with the launch of Falcon 180B, an advanced iteration of its flagship large language model (LLM). This groundbreaking release strengthens the UAE's dominance in AI, offering Falcon 180B as an open access model for research and commercial purposes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230906583274/en/
Falcon 180B Benchmarks (Photo: AETOSWire)
Following the remarkable success of Falcon 40B, an open source AI model that swiftly ascended to the top of the Hugging Face Leaderboard for LLMs in May 2023, TII, the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC) continues to lead the charge in generative AI. Falcon 40B marked one of the first instances of open source models for both researchers and commercial users, and it was considered a pioneering leap in the field.
H.E. Faisal Al Bannai, Secretary General of the Advanced Technology Research Council, emphasized the positive impact of Falcon on the AI landscape and said: “We envision a future where the transformative power of AI is within everyone's reach. We are committed to democratizing access to advanced AI, as our privacy and the potential impact of AI on humanity should not be controlled by a select few. While we may not have all the answers, our resolve remains unwavering: to collaborate and contribute to the open source community, ensuring that the benefits of AI are shared by all.”
With a staggering 180 billion parameters and trained on 3.5 trillion tokens, Falcon 180B soars to the top of the Hugging Face Leaderboard for pretrained LLMs. It outperforms notable competitors like Meta’s LLaMA 2 in various benchmarks, including reasoning, coding, proficiency, and knowledge tests.
Among the best closed source LLMs, Falcon 180B ranks just behind OpenAI's latest GPT 4 and is on par with the performance of Google's PaLM 2 Large, the model powering Bard – despite being half the size of the model. The licensing framework for the model is established on ‘Falcon 180B TII License’, which is based upon Apache 2.0.
Dr. Ebtesam Almazrouei, Executive Director and Acting Chief Researcher of the AI Cross-Center Unit at TII, said: "The launch of Falcon 180B exemplifies our dedication to advancing the frontiers of AI, and we are thrilled to share its limitless potential with the world. Falcon 180B heralds a new era of generative AI, where the potential of scientific advancement is made available through open access to fuel the innovations of tomorrow. As we delve into frontiers of science and technology, our vision extends far beyond innovation; it's about nurturing a profound connection to address global challenges through collaborative breakthroughs.”
With over 12 million developers adopting and deploying the first release of Falcon, this significant upgrade is poised to become the premier model for various domains, from chatbots to code generation, and beyond.
Falcon 180B is compatible with the following major languages: English, German, Spanish, and French, with limited capabilities in Italian, Portuguese, Polish, Dutch, Romanian, Czech, and Swedish.
For more information, please visit FalconLLM.tii.ae
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230906583274/en/
Contact information
Jennifer Dewan, Senior Director of Communications
jennifer.dewan@tii.ae.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom